Genmab A-S

Затворен

2,236 -1.71

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2264

Максимум

2286

Ключови измерители

By Trading Economics

Приходи

243M

295M

Продажби

259M

1.2B

P/E

Средно за сектора

26.002

56.432

EPS

34.85

Марж на печалбата

25.541

Служители

3,119

EBITDA

216M

431M

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

-1.49% downside

Дивиденти

By Acuity

Следващи печалби

5.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

17B

130B

Предишно отваряне

2237.71

Предишно затваряне

2236

Genmab A-S Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.09.2026 г., 23:31 ч. UTC

China's Loan Prime Rate announcement on September 21, 2026, is anticipated at 0.03%, amid global tightening trends influenced by rising inflation and Japan's recent rate hike to 1.25%.

19.09.2026 г., 23:31 ч. UTC

China's Loan Prime Rate expected to hold at 3.50% on September 21, amid stable market sentiment and focus on international cooperation.

19.09.2026 г., 23:11 ч. UTC

U.S. Mortgage Rates Hit 6.97% Amid Fed Rate Hike and Inflation Concerns, Signaling Potential Further Increases Ahead

19.09.2026 г., 23:11 ч. UTC

Cautious Market Sentiment Ahead of Chicago Fed National Activity Index Release Amid Disappointing Economic Indicators

19.09.2026 г., 23:01 ч. UTC

Avalanche is advancing sharply, continuing its strong upward trend, despite earlier pulling back from a session high, and trading well above its 20-day moving average.

19.09.2026 г., 23:01 ч. UTC

Correlated Moves

XRP is advancing, continuing its upward trend since Friday's close, influenced by ongoing geopolitical tensions and recent interest rate hikes by major central banks.

19.09.2026 г., 22:51 ч. UTC

Correlated Moves

The Russell 2000 Index is little changed in after-market hours, remaining near the lower end of its one-month range amid ongoing geopolitical tensions.

19.09.2026 г., 22:51 ч. UTC

Correlated Moves
Macro News

The Dow Jones Index (US) is trading lower in after-market hours, reflecting minimal movement since Friday's close amid ongoing geopolitical tensions and a new Lockheed Martin contract.

19.09.2026 г., 22:51 ч. UTC

The FTSE 100 Index is trading lower in after-market hours, positioned below its 20-day moving average amid ongoing geopolitical tensions affecting energy prices.

19.09.2026 г., 22:31 ч. UTC

UK Consumer Confidence Index Forecasted at -16.0 Amid Cautious Market Sentiment and Rising Cost-of-Living Concerns

19.09.2026 г., 21:41 ч. UTC

Australia's S&P Global Manufacturing PMI Flash set for September 22, with market expectations at neutral 50 amid cautious optimism and inflation concerns.

19.09.2026 г., 21:41 ч. UTC

Australia's S&P Global Services PMI Flash release on September 22 faces cautious optimism amid mixed economic signals and global inflation concerns.

19.09.2026 г., 21:21 ч. UTC

Brazil's Central Bank to Release COPOM Meeting Minutes Amid Global Interest Rate Shifts, Influencing Market Sentiment on SELIC Decisions

19.09.2026 г., 21:11 ч. UTC

UK CBI Distributive Trades Forecasts -50.0 Amidst Recent Retail Sales Rebound, Indicating Mixed Consumer Sentiment Ahead of Q4

19.09.2026 г., 20:41 ч. UTC

UK Manufacturing Sector Faces Caution Ahead of September 2026 CBI Industrial Trends Orders Forecasted at -35.0 Amid Mixed Economic Signals and Rising Cost Pressures.

19.09.2026 г., 20:41 ч. UTC

API Crude Oil Stock Change Data Release on September 22, 2026, Amidst Volatile Market Influenced by Geopolitical Tensions and Mixed Investor Sentiment.

19.09.2026 г., 19:41 ч. UTC

South Korea's Consumer Confidence Index set for release amid bearish market sentiment and rising interest rates, signaling potential consumer caution.

19.09.2026 г., 19:41 ч. UTC

Correlated Moves

EUR/NZD is roughly flat since Friday's close, maintaining stability while the market is closed for the weekend and reflecting its position near the upper end of its one-month range.

19.09.2026 г., 19:41 ч. UTC

Macro News

Volkswagen's fiscal outlook revision due to Porsche AG goodwill impairment is contributing to a decline in the IBEX 35 Index amid rising geopolitical tensions.

19.09.2026 г., 19:41 ч. UTC

Macro News

The A50 Index (China) is modestly higher in after-market trading, amid rising geopolitical tensions and central bank interest rate hikes affecting risk assets.

19.09.2026 г., 19:11 ч. UTC

Germany's Ifo Business Climate Index set for September 24 release amid cautious market sentiment and rising inflation expectations.

19.09.2026 г., 18:51 ч. UTC

Investors Brace for Cautious S&P Global Composite PMI Flash Release Amid Rising Inflation Concerns in Euro Area

19.09.2026 г., 18:51 ч. UTC

South Africa's Inflation Rate Set for Release Amid Cautious Market Sentiment Following July Decline to 4.3%.

19.09.2026 г., 18:51 ч. UTC

Investors Brace for S&P Global Services PMI Flash Release Amid Rising Inflation Concerns and Mixed Economic Signals in Euro Area

19.09.2026 г., 18:51 ч. UTC

Euro Area's S&P Global Manufacturing PMI Flash set for September 23, with forecasted growth amid rising inflation concerns and cautious investor sentiment.

19.09.2026 г., 18:51 ч. UTC

South Africa's Inflation Rate Release on September 23, 2026 Sparks Caution Among Investors Amid Global Economic Pressures.

19.09.2026 г., 18:41 ч. UTC

SNB Expected to Maintain 0% Interest Rate Amid Low Inflation and Strong Franc Ahead of September Decision

19.09.2026 г., 18:31 ч. UTC

Spain's Balance of Trade report on September 22, 2026, raises concerns over systemic trade deficits amid rising inflation and cautious market sentiment.

19.09.2026 г., 18:21 ч. UTC

Germany's S&P Global Services PMI Flash set for September 23, with cautious market sentiment amid rising inflation expectations and mixed economic indicators.

19.09.2026 г., 18:21 ч. UTC

Germany's S&P Global Composite PMI Flash Release on September 23 Expected to Reflect Economic Challenges Amid Inflation and Geopolitical Uncertainty.

Сравнение с други в отрасъла

Ценова промяна

Genmab A-S Прогноза

Ценова цел

By TipRanks

-1.49% надолу

12-месечна прогноза

Среден 2,493.35 DKK  -1.49%

Висок 3,320 DKK

Нисък 308.417 DKK

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Genmab A-S през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

7 ratings

3

Купи

2

Задържане

2

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.